We are all so focussed on NanoDX delivering there Covid19 solution we tend to forget that the FDA BreakThrough Designation was obtained for the work being done by NanoDX on Traumatic Brain Injury ( TBI ). Indeed, this was the application that Sensera had been working with NanoDiagnostics on for 18 months before Covid19 reared it's ugly head. In scanning the internet for any news on NanoDX/Covid19 I frequently come across references to the TBI application. It seems this has been getting some real traction in the medical science community. NanoDX will be a foundation building company for Sensera, in the immediate future from the Covid19 application, but then on an ongoing basis for the TBI, sepsis and stroke applications.
Here is another reference that appeared this morning, the Medical Tech Outlooks magazine nominating the 10 best neurology solution companies for 2021, in which NanoDX features.
